Canadian Large Cap Leaders Split Corp. Receives Approval for Normal Course Issuer Bid
TORONTO, June 04, 2025 (GLOBE NEWSWIRE) — Ninepoint Partners LP ('Ninepoint'), on behalf of Canadian Large Cap Leaders Split Corp. (the 'Company') (TSX: NPS/NPS.PR.A), announced today that the Toronto Stock Exchange (the 'TSX') has accepted its notice of intention to make a normal course issuer bid (the 'NCIB') to purchase its class A shares ('Class A Shares') and preferred shares ('Preferred Shares') through the facilities of the TSX and alternative trading systems in Canada. The NCIB will commence on June 9, 2025 and terminate on June 8, 2026.
Pursuant to the NCIB, the Company proposes to purchase, from time to time, up to 176,492 Class A Shares and 176,492 Preferred Shares of the Company, representing 10% of the public float of 1,764,915 Class A Shares and 1,764,915 Preferred Shares. As of June 4th, 2025, there were 1,764,915 Class A Shares and 1,764,915 Preferred Shares issued and outstanding. The Company will not purchase, in any given 30-day period, in the aggregate, more than 35,298 Class A Shares or more than 35,298 Preferred Shares, being 2% of the issued and outstanding Class A Shares and Preferred Shares as of June 4th, 2025.
Under Ninepoint Partners prior NCIB, which commenced on May 28, 2024 and ended on May 27, 2025, Ninepoint Partners obtained approval to purchase up to a total of 209,947 Common Shares, reflecting a security split that took effect on Feb 4, 2025, and 182,563 Preferred Shares, of which 49,450, on the post-split basis, Common Shares, and 43,000 Preferred Shares were purchased through the facilities of the TSX at a weighted-average price of approximately $10.39, on the post-split basis, per Common Share, and $10.45 for Preferred Shares.
Ninepoint, the manager of the Company, believes that such purchases are in the best interests of the Company and are a desirable use of its funds. All purchases will be made through the facilities noted above and in accordance with the rules and policies of the TSX. All Class A Shares or Preferred Shares purchased by the Company pursuant to the NCIB will be cancelled.
About Ninepoint Partners LP
Based in Toronto, Ninepoint Partners LP is one of Canada's leading alternative investment management firms overseeing approximately $7 billion in assets under management and institutional contracts. Committed to helping investors explore innovative investment solutions that have the potential to enhance returns and manage portfolio risk, Ninepoint offers a diverse set of alternative strategies spanning Equities, Fixed Income, Alternative Income, Real Assets, F/X and Digital Assets.
For more information on Ninepoint, please visit
www.ninepoint.com
or for inquiries regarding the Offering, please contact us at (416) 943-6707 or (866) 299-9906 or
invest@ninepoint.com
.
Certain statements included in this news release constitute forward-looking statements, including, but not limited to, those identified by the expressions 'expects', 'intends', 'anticipates', 'will' and similar expressions to the extent that they relate to the Company. The forward-looking statements are not historical facts but reflect Ninepoint's current expectations regarding future results or events. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Although Ninepoint believes the assumptions inherent in the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance and, accordingly, readers are cautioned not to place undue reliance on such statements due to the inherent uncertainty therein. Neither the Company nor Ninepoint undertake any obligation to update publicly or otherwise revise any forward-looking statement or information whether as a result of new information, future events or other such factors which affect this information, except as required by law.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
30 minutes ago
- Business Wire
NIQ Announces Pricing of Initial Public Offering
CHICAGO--(BUSINESS WIRE)--NIQ Global Intelligence plc (the 'Company') announced today the pricing of its initial public offering of 50,000,000 of its ordinary shares at a public offering price of $21.00 per ordinary share. The underwriters will have a 30-day option to purchase up to an additional 7,500,000 ordinary shares from the selling shareholder at the initial public offering price less underwriting discounts and commissions. The Company's ordinary shares are expected to begin trading on the New York Stock Exchange on July 23, 2025, under the ticker symbol 'NIQ.' The offering is expected to close on July 24, 2025, subject to customary closing conditions. The Company intends to use the net proceeds that it receives from the offering, together with available cash, as necessary, to repay amounts outstanding under its revolving credit facility and a portion of the amounts outstanding under its US term loan facility and to use any remaining net proceeds for working capital and for general corporate purposes. The Company will not receive any proceeds from the sale of ordinary shares by the selling shareholder. J.P. Morgan, BofA Securities, UBS Investment Bank, Barclays and RBC Capital Markets are acting as joint lead book-running managers for the offering. Citigroup, Wells Fargo Securities, BNP Paribas, Deutsche Bank Securities, BMO Capital Markets and KKR are also acting as joint book-running managers. Baird, Needham & Company, Stifel, William Blair, Capital One Securities, Fifth Third Securities, SMBC Nikko, Academy Securities, Loop Capital Markets and Roberts & Ryan are acting as co-managers for the offering. This offering is being made only by means of a prospectus. Copies of the final prospectus relating to this offering, when available, may be obtained from: J.P. Morgan Securities LLC, Attention: c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or email: prospectus-eq_fi@ and postsalemanualrequests@ BofA Securities, Inc., NC1-022-02-25, 201 North Tryon Street, Charlotte, NC 28255-0001, Attention: Prospectus Department, by email: or UBS Securities LLC, 1285 6th Ave, New York, NY 10019, by telephone: (888) 827-7275. A registration statement on Form S-1 relating to the offering was declared effective by the Securities and Exchange Commission on July 22, 2025. This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About NIQ NIQ is a leading consumer intelligence company, delivering the most complete understanding of consumer buying behavior and revealing new pathways to growth. NIQ combined with GfK in 2023, bringing together two industry leaders with unparalleled global reach. Our global reach spans over 90 countries covering approximately 85% of the world's population and more than $ 7.2 trillion in global consumer spend. With a holistic retail read and the most comprehensive consumer insights—delivered with advanced analytics through state-of-the-art platforms—NIQ delivers the Full View™. NIQ-IR
Hamilton Spectator
an hour ago
- Hamilton Spectator
Diversified Royalty Corp. Announces Filing of Final Short Form Base Shelf Prospectus
VANCOUVER, British Columbia, July 22, 2025 (GLOBE NEWSWIRE) — Diversified Royalty Corp. (TSX: DIV and (the 'Corporation' or 'DIV') announced today that it has filed, and received receipt for, a final short form base shelf prospectus (the 'Prospectus'). The Prospectus was filed with the securities regulatory authorities in each of the provinces and territories of Canada. DIV's prior short form base shelf prospectus dated June 19, 2023, expired on July 19, 2025. Accordingly, DIV filed the Prospectus to maintain financial flexibility and efficient access to Canadian capital markets to pursue strategic initiatives. A copy of the Prospectus is available under DIV's profile on SEDAR+ at . The Prospectus is valid for a 25-month period during which time DIV may, from time to time, issue common shares, warrants, subscription receipts, debt securities, convertible securities or rights or any combination thereof, including in the form of units (collectively, the 'Securities'). The specific terms of any offering of Securities will be described in one or more shelf prospectus supplements which will be filed at the time of the offering of such Securities. There is no certainty any Securities will be offered or sold under the Prospectus within the 25-month effective period. About Diversified Royalty Corp. DIV is a multi-royalty corporation, engaged in the business of acquiring top-line royalties from well-managed multi-location businesses and franchisors in North America. DIV's objective is to acquire predictable, growing royalty streams from a diverse group of multi-location businesses and franchisors. DIV currently owns the Mr. Lube + Tires, AIR MILES®, Sutton, Mr. Mikes, Nurse Next Door, Oxford Learning Centres, Stratus Building Solutions, BarBurrito and Cheba Hut trademarks. Mr. Lube + Tires is the leading quick lube service business in Canada, with locations across Canada. AIR MILES® is Canada's largest coalition loyalty program. Sutton is among the leading residential real estate brokerage franchisor businesses in Canada. Mr. Mikes operates casual steakhouse restaurants primarily in western Canadian communities. Nurse Next Door is a home care provider with locations across Canada and the United States as well as in Australia. Oxford Learning Centres is one of Canada's leading franchisee supplemental education services. Stratus Building Solutions is a leading commercial cleaning service franchise company providing comprehensive janitorial, building cleaning, and office cleaning services primarily in the United States. BarBurrito is the largest quick service Mexican restaurant food chain in Canada. Cheba Hut is a fast casual toasted sub sandwich franchise with locations in the United States. DIV's objective is to increase cash flow per share by making accretive royalty purchases and through the growth of purchased royalties. DIV intends to continue to pay a predictable and stable monthly dividend to shareholders and increase the dividend over time, in each case as cash flow per share allows. Forward-Looking Information Certain statements contained in this news release may constitute 'forward-looking information' within the meaning of applicable securities laws that involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking information. The use of any of the words 'anticipate', 'continue', 'estimate', 'expect', 'intend', 'may', 'will', 'project', 'should', 'believe', 'confident', 'plan' and 'intends' and similar expressions are intended to identify forward-looking information, although not all forward-looking information contains these identifying words. Specifically, forward-looking information in this news release includes, but is not limited to, statements made in relation to: the Prospectus being filed to provide DIV with financial flexibility and efficient access to Canadian capital markets to pursue strategic initiatives; the specific terms of any offering of Securities will be described in one or more shelf prospectus supplements which will be filed at the time of the offering of such Securities; DIV's objective to continue to pay predictable and stable monthly dividends to shareholders; and DIV's corporate objectives. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events, performance, or achievements of DIV to differ materially from those anticipated or implied by such forward-looking information. DIV believes that the expectations reflected in the forward-looking information included in this news release are reasonable but no assurance can be given that these expectations will prove to be correct. In particular there can be no assurance that: DIV will complete any offerings of Securities under the Prospectus; DIV will be able to make monthly dividend payments to the holders of its common shares; or DIV will achieve any of its corporate objectives. Given these uncertainties, readers are cautioned that forward-looking information included in this news release are not guarantees of future performance, and such forward-looking information should not be unduly relied upon. More information about the risks and uncertainties affecting DIV's business and the businesses of its royalty partners can be found in the 'Risk Factors' section of its Annual Information Form dated March 24, 2025 and in its most recent Management's Discussion and Analysis, copies of each of which are available under DIV's profile on SEDAR+ at . In formulating the forward-looking information contained herein, management has assumed that, among other things: DIV will complete one or more offerings of Securities under the Prospectus and one or more shelf prospectus supplements and DIV will successfully deploy the proceeds therefrom; DIV will generate sufficient cash flows from its royalties to service its debt and pay dividends to shareholders; the business and economic conditions affecting DIV and its royalty partners will continue substantially in the ordinary course, including without limitation with respect to general industry conditions, general levels of economic activity and regulations. These assumptions, although considered reasonable by management at the time of preparation, may prove to be incorrect. All of the forward-looking information in this news release is qualified by these cautionary statements and other cautionary statements or factors contained herein, and there can be no assurance that the actual results or developments will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, DIV. The forward-looking information included in this news release is presented as of the date of this news release and DIV assumes no obligation to publicly update or revise such information to reflect new events or circumstances, except as may be required by applicable law. THE TORONTO STOCK EXCHANGE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR THE ACCURACY OF THIS RELEASE. Additional Information Additional information relating to the Corporation and other public filings, is available on SEDAR+ at . Contact: Sean Morrison, Chief Executive Officer and Director Diversified Royalty Corp. (236) 521-8470 Greg Gutmanis, President and Chief Financial Officer Diversified Royalty Corp. (236) 521-8471
Hamilton Spectator
2 hours ago
- Hamilton Spectator
XORTX Completes Non-Brokered Private Placement of Units
Not For Distribution to United States News Wire Services or for Dissemination in the United States CALGARY, Alberta, July 22, 2025 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. ('XORTX' or the 'Company') (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to announce the closing of its previously announced non-brokered private placement of units ('Units'), whereby it issued 1,267,123 Units at a price of US$0.73 per Unit for aggregate gross proceeds of US$925,000 pursuant to the listed issuer financing exemption under Part 5A of National Instrument 45-106 – Prospectus Exemptions (the 'Offering'). Under the Offering, each Unit consisted of one common share in the capital of the Company ('Common Share') and one common share purchase warrant ('Warrant'). Each Warrant entitles the holder thereof to purchase one additional Common Share at a price of US$1.20 for a period of sixty (60) months following the date of issuance provided, however, that if the closing price of the Common Shares on the Nasdaq is greater than US$2.00 for ten (10) or more consecutive trading days, the Warrants will be accelerated and will expire on the 30th business day following the date of such notice. Closing of the Offering was approved by the TSX Venture Exchange ('TSXV'), and the securities issued under the Offering will not be subject to a four-month and one-day statutory hold period. The Company intends to use the proceeds of the Offering as more specifically described in the Offering Document and for gout programs, general corporate and working capital purposes. In connection with the Offering, the Company paid an aggregate of $12,264 in finder's fees and issued, in aggregate, 16,800 finder's warrants. The securities have not and will not be registered under the U.S. Securities Act of 1933, as amended (the 'U.S. Securities Act'), or any applicable state securities laws and may not be offered or sold to, or for the account or benefit of, persons in the United States or 'U.S. persons,' as such term is defined in Regulation S promulgated under the U.S. Securities Act, absent registration or an exemption from such registration requirements. This news release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation, or sale would be unlawful. The issuance of 8,191 Units to an insider of the Company constitutes a 'related party transaction' as such term is defined in Multilateral Instrument 61-101 – Protection of Minority Securityholders in Special Transactions ('MI 61-101'). Pursuant to Sections 5.5(a) and 5.7(1)(a) of MI 61-101, the Company relied on exemptions from the formal valuation and minority shareholder approval requirements, respectively, as neither the fair market value of the Units nor the consideration for such Units, insofar as it involves the insider, exceeds 25 percent of the Company's market capitalization. In other news, the non-brokered private placement that was announced on May 19, 2025 will not proceed. About XORTX Therapeutics Inc. XORTX is a pharmaceutical company with three clinically advanced products in development: 1) our lead program XRx-026 program for the treatment of gout; 2) XRx-008 program for ADPKD; and 3) XRx-101 for acute kidney and other acute organ injury associated with respiratory virus infections. In addition, the Company is developing XRx-225, a pre-clinical stage program for Type 2 diabetic nephropathy. XORTX is working to advance products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. At XORTX, we are dedicated to developing medications that improve the quality of life and health of individuals with gout and other important diseases. Additional information on XORTX is available at . For more information, please contact: Forward-Looking Statements Statements contained in this news release that are not historical facts are 'forward-looking information' or 'forward-looking statements' within the meaning of applicable Canadian securities laws. Such forward-looking statements or information are provided to inform the Company's shareholders and potential investors about management's current expectations and plans relating to the future. Readers are cautioned that reliance on such information may not be appropriate for other purposes. Any such forward-looking information may be identified by words such as 'anticipate', 'proposed', 'estimates', 'would', 'expects', 'intends', 'plans', 'may', 'will', and similar expressions, although not all forward-looking information contains these identifying words. More particularly and without limitation, the forward-looking information in this news release includes (i) expectations regarding the Company's current and future financing plans; (ii) expectations concerning the Company's plans and objectives in respect of the Offering's gross proceeds; and (iii) expectations regarding the Company's business plans and operations. Forward-looking information is based on a number of factors and assumptions that have been used to develop such information, but which may prove to be incorrect and are inherently subject to significant business, economic and competitive uncertainties, and contingencies. The material factors and assumptions used in preparing the forward-looking information contained herein include, among others, our ability to obtain additional financing; the accuracy of our estimates regarding expenses, future revenues and capital requirements; the success and timing of our preclinical studies and clinical trials; the performance of third-party manufacturers and contract research organizations; our plans to develop and commercialize our product candidates; our plans to advance research in other kidney disease applications; and our ability to obtain and maintain intellectual property protection for our product candidates. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, undue reliance should not be placed on forward-looking information because the Company can give no assurance that such expectations will prove to be correct. The forward-looking information in this news release reflects the Company's current expectations, assumptions and/or beliefs based on information currently available to the Company. Any forward-looking information speaks only as of the date on which it is made and, except as may be required by applicable securities laws, the Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or expressly qualified by this cautionary statement. More detailed information about the risks and uncertainties affecting XORTX is contained under the heading 'Risk Factors' in XORTX's Annual Report on Form 20-F filed with the SEC, which is available on the SEC's website, (including any documents forming a part thereof or incorporated by reference therein), as well as in our reports, public disclosure documents and other filings with the securities commissions and other regulatory bodies in Canada, which are available on . Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy of this release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.
